

Table 1. Baseline Characteristics of Included Patients by Baseline Statin Use in the Pooled BP Management Arms

Patient Characteristic	Patients Aged ≥ 70 Years, No Clinical CVD at Baseline, Mean (SD)		P Value
	Statin Use at Baseline (n = 1334)	No Baseline Statin Use (n = 1685)	
Primary event rate, % ^a	6.4 (0.7)	7.8 (0.7)	.14
Age, y	77.1 (0.1)	77.0 (0.2)	.55
Female sex, %	38.6 (1.3)	46.6 (1.2)	<.001
African American, %	21.4 (1.1)	21.9 (1.0)	.72
BMI	28.6 (0.1)	28.1 (0.1)	.003
Current smoker, %	3.7 (0.5)	2.7 (0.4)	.14
Systolic BP, mm Hg	140.2 (0.4)	142.5 (0.4)	<.001
Diastolic BP, mm Hg	72.7 (0.3)	74.1 (0.3)	<.001
BP agents, No.	2.0 (0.0)	1.7 (0.0)	<.001
Chronic renal disease, %	42.1 (1.4)	36.0 (1.1)	<.001
Serum creatinine, mg/dL	1.1 (0.0)	1.1 (0.0)	<.001
Estimated GFR rate, ml/min/1.73 m ²	65.1 (0.5)	66.6 (0.5)	.03
Urinary albumin/creatinine ratio, mg/g	45.7 (4.4)	46.2 (3.8)	.94
Fasting plasma glucose, mg/dL	99.2 (0.3)	97.1 (0.3)	<.001
Fasting total cholesterol, mg/dL	175.6 (1.0)	199.0 (0.9)	<.001
Fasting total high-density lipoprotein cholesterol, mg/dL	55.6 (0.4)	57.0 (0.4)	.01
Fasting total triglycerides, mg/dL	113.0 (1.6)	112.4 (1.6)	.80
Aspirin use, %	62.0 (1.3)	44.9 (1.2)	<.001
Framingham 10-year risk of CVD, %	22.3 (0.3)	25.1 (0.3)	<.001

Abbreviations: BP, blood pressure; BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); CVD, cardiovascular disease; GFR, glomerular filtration rate. SI conversion factors: To convert serum creatinine to $\mu\text{mol/L}$, multiply by 88.4; plasma glucose to mmol/L , multiply by 0.0555; total cholesterol to mmol/L , multiply by 0.0259; and total triglycerides to mmol/L , multiply by 0.0113.

^a Median follow-up of 1120 d among statin users, vs 1104 d not taking statins at baseline ($P = .22$).

Table 2. Baseline Statin Use Effect on Primary Events Adjusting for Nonrandom Statin Assignment^a

Model	Age ≥65 Years	Age ≥70Years
Treatment Effects Model, Estimated Event Rates Over Trial (95% CI)		
All with baseline statin use	0.060 (0.045 to 0.075)	0.063 (0.045 to 0.081)
All without baseline statin use	0.065 (0.054 to 0.077)	0.081 (0.066 to 0.096)
Average rate reduction with statin use	0.005 (-0.014 to 0.024)	0.018 (-0.005 to 0.040)
Survival Model, Estimated Days to Event Over Trial (95% CI)		
All with baseline statin use	688.3 (594.3 to 782.2)	669.2 (561.9 to 776.4)
All without baseline statin use	774.8 (695.5 to 854.2)	753.8 (671.6 to 836.0)
Average time reduction with statin use ^b	86.6 (-36.4 to 209.5)	84.6 (-50.7 to 220.0)

^a Analyses include patients without baseline cardiovascular disease, regardless of randomization to intensive and standard BP management arms. All models used inverse probability weighting to adjust for nonrandom statin use.

^b A reduction in time to event implies higher hazard rate.